AbbVie Inc (ABBV)vsEmbecta Corp (EMBC)
ABBV
AbbVie Inc
$205.03
-0.52%
HEALTHCARE · Cap: $365.43B
EMBC
Embecta Corp
$3.90
-57.84%
HEALTHCARE · Cap: $547.78M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 5718% more annual revenue ($62.82B vs $1.08B). EMBC leads profitability with a 12.9% profit margin vs 5.8%. EMBC trades at a lower P/E of 3.9x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
EMBC
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.6%
Fair Value
$168.19
Current Price
$205.03
$36.84 premium
Margin of Safety
+78.6%
Fair Value
$46.96
Current Price
$3.90
$43.06 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Attractively priced relative to earnings
Earnings expanding 82.7% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 29.2%
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 0.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, EPS Growth, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.8x leaves little room for execution misses.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while EMBC is a declining play — different risk/reward profiles.
EMBC carries more volatility with a beta of 1.05 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 56/100) and 12.4% revenue growth. EMBC offers better value entry with a 78.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a premier medical technology company specializing in innovative insulin delivery solutions for diabetes management. As a strategic spin-off from Becton, Dickinson and Company, Embecta utilizes state-of-the-art technologies and a diverse product portfolio, including insulin pens and syringes, to optimize patient care and improve health outcomes. With a strong commitment to operational excellence and a customer-centric approach, Embecta is well-positioned to seize growth opportunities in the rapidly evolving diabetes care market, aiming to enhance patient experiences while solidifying its leadership within the industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?